Overview

PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)

Status:
Terminated
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Currently enrolling melanoma patients in combination with nivolumab, only.
Phase:
Phase 1
Details
Lead Sponsor:
Karyopharm Therapeutics Inc
Karyopharm Therapeutics, Inc
Treatments:
Niacin
Niacinamide
Nicotinic Acids
Nivolumab